Dataset from A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease (UNITI-2)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/00004834
下载链接
链接失效反馈官方服务：
资源简介：
This study (UNITI-2) will compare the effects (both positive and negative) of an initial treatment with ustekinumab to a placebo over 8 weeks in patients with moderately to severely active Crohn's disease.
创建时间：
2026-03-02
